ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
0.00%
Dow Jones
38,675.68
0.00%
US Dollar vs MXN
16.93163
-0.31%
Brent Oil
83.575
0.54%
Bitcoin
63,648.58
-0.55%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Lexaria Bioscience Corporation (LEXX)

  7. Lexaria Bioscience Corporation (LEXX) Noticias

LEXX

Lexaria Bioscience (LEXX)

Lexaria Bioscience Corporation
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:LEXX
FechaHoraFuenteTítuloSímboloCompañía
06/03/202405:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:LEXXLexaria Bioscience Corporation
01/03/202413:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
16/02/202414:47Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:LEXXLexaria Bioscience Corporation
16/02/202405:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LEXXLexaria Bioscience Corporation
14/02/202413:20Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LEXXLexaria Bioscience Corporation
14/02/202411:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LEXXLexaria Bioscience Corporation
28/01/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LEXXLexaria Bioscience Corporation
24/01/202412:33Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:LEXXLexaria Bioscience Corporation
18/01/202413:38Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LEXXLexaria Bioscience Corporation
12/01/202416:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LEXXLexaria Bioscience Corporation
11/01/202407:30GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter BloodstreamNASDAQ:LEXXLexaria Bioscience Corporation
10/01/202407:45InvestorsHub NewsWireGLP-1: Beyond Diabetes, a Blockbuster Horizon BeckonsNASDAQ:LEXXLexaria Bioscience Corporation
09/01/202407:30GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery PlatformNASDAQ:LEXXLexaria Bioscience Corporation
08/01/202407:45InvestorsHub NewsWireExciting New Cures Possible from GLP-1 Diabetes, Weight-Loss DrugsNASDAQ:LEXXLexaria Bioscience Corporation
08/12/202315:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LEXXLexaria Bioscience Corporation
30/11/202315:14Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:LEXXLexaria Bioscience Corporation
20/11/202316:16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LEXXLexaria Bioscience Corporation
01/11/202312:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LEXXLexaria Bioscience Corporation
01/11/202307:45InvestorsHub NewsWireGet Ready for Next Generation of Diabetes, Weight-Management DrugsNASDAQ:LEXXLexaria Bioscience Corporation
01/11/202307:30GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug SpaceNASDAQ:LEXXLexaria Bioscience Corporation
31/10/202307:31GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 DrugsNASDAQ:LEXXLexaria Bioscience Corporation
30/10/202307:45InvestorsHub NewsWireCan Diabetes, Weight-Loss Drugs Get Even Better?NASDAQ:LEXXLexaria Bioscience Corporation
18/09/202309:42Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:LEXXLexaria Bioscience Corporation
09/08/202311:35Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:LEXXLexaria Bioscience Corporation
23/06/202315:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LEXXLexaria Bioscience Corporation
10/05/202315:31Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:LEXXLexaria Bioscience Corporation
09/05/202305:04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:LEXXLexaria Bioscience Corporation
28/04/202315:44Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:LEXXLexaria Bioscience Corporation
14/04/202311:45Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LEXXLexaria Bioscience Corporation
22/03/202307:04Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:LEXXLexaria Bioscience Corporation
 Showing the most relevant articles for your search:NASDAQ:LEXX

Su Consulta Reciente

AMEX
SPY
SPDR S&P 500
NASDAQ
GOOGL
Alphabet
NYSE
VZ
Verizon Communications
CCOM
SILVER
SILVER
NASDAQ
AAPL
Apple
CCOM
OILBRENT
Brent Oil
CCOM
US30
US 30
COIN
BTCUSD
Bitcoin
NYSE
MRK
Merck
NASDAQ
AMZN
Amazon.com
AMEX
XLF
Financial Select Sector
FX
EURMXN
Euro vs MXN
FX
USDMXN
US Dollar vs MXN
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
AXP
American Express
COIN
SOLUSD
Solana
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados